Termination for Patent Challenge. FibroGen may terminate this Agreement in its entirety immediately upon written notice to AstraZeneca if AstraZeneca or its Affiliates or Sublicensees (directly or indirectly, individually or in association with any other person or entity) challenges the validity, enforceability or scope of any FibroGen Patent in the Territory and such challenge is not permanently withdrawn within ninety (90) days.
Appears in 5 contracts
Samples: Development and Commercialization Agreement (Fibrogen Inc), License, Development and Commercialization Agreement, Development and Commercialization Agreement (Fibrogen Inc)
Termination for Patent Challenge. FibroGen China may terminate this Agreement in its entirety immediately upon written notice to AstraZeneca if AstraZeneca or its Affiliates or Sublicensees sublicensees (directly or indirectly, individually or in association with any other person or entity) challenges the validity, enforceability or scope of any FibroGen China Patent in the Territory and such challenge is not permanently withdrawn within ninety (90) days.
Appears in 3 contracts
Samples: Development and Commercialization Agreement (Fibrogen Inc), Fibrogen Inc, Development and Commercialization Agreement (Fibrogen Inc)
